Roche holds the cleaner structural position, with profitability as the main driver and valuation adding further support. Amgen still has the edge on valuation, which keeps the comparison from looking entirely one-sided. The market setup is broadly comparable for both — no clear directional signal from price behavior. The market is not adding a decisive signal either way — the structural read carries the weight.
The comparison is based on similar long-term financial trajectories, not sector labels. Peer scores are normalised within each company's primary universe (AMGN: Nasdaq 100, ROP.SW: STOXX 600).
The clearest separation starts in profitability, with growth adding a second layer of support. Roche Holding AG leads by 9 points on the overall comparison score.
Both operate in: Drug Manufacturers - General
This comparison is based on industry proximity, not on functional trajectory similarity. AMGN and ROP.SW share the same industry classification.
For a similarity-based comparison, see how Amgen and Roche each position within their functional peer groups in AssetNext.
Scores reflect position relative to comparable companies with similar long-term financial trajectories.
The largest gaps do not all point in the same direction.
Left means cheaper relative valuation. Higher means stronger structure.
Roche Holding AG is cheaper, but Amgen Inc. is still stronger.
Valuation position uses peer-relative PE percentile (idx_pct_pe) where available.
Where AMGN and ROP.SW each sit in their own 5-year price and valuation history.
Describes historical entry positioning only. Descriptive — not investment advice.
Capital efficiency adds support, with a 13.2-point ROIC advantage.
Valuation still leans toward Amgen Inc., so the lead is real without reading as one-way.
Profitability is the clearest driver of the lead, with valuation adding further support — though valuation still provides a real counterweight.
Break down the AMGN vs ROP.SW comparison across all dimensions with the full interactive tool.
Explore how AMGN and ROP.SW each compare against other companies in their peer groups.
Rule-based, descriptive analysis only. Derived from peer percentile dimensions. Not investment advice. Peer groups are determined algorithmically based on structural similarity — not by sector classification alone.
AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.
Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.
Because scores are peer-relative, the same company can have slightly different scores in different index universes. On comparison pages, both companies are shown within their shared peer universe wherever possible — so the scores are directly comparable. The peer basis is stated on each score card.
Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.